PMID- 26929034
OWN - NLM
STAT- MEDLINE
DCOM- 20170317
LR  - 20211204
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 63
IP  - 7
DP  - 2016 Jul
TI  - Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent 
      Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous 
      Sclerosis Complex.
PG  - 1276-8
LID - 10.1002/pbc.25964 [doi]
AB  - The majority of patients with subependymal giant cell astrocytoma (SEGA) have 
      tuberous sclerosis complex (TSC). In such patients, the mammalian target of 
      rapamycin (mTOR) inhibitor everolimus has been shown to induce responses. 
      Isolated SEGA have been reported in patients without clinical or genetic features 
      of TSC. The treatment of these patients with everolimus has not previously been 
      reported. We treated a patient with a recurrent isolated SEGA with an mTOR 
      inhibitor. The patient tolerated therapy well and had a sustained complete 
      remission. MTOR inhibitors may be useful for the treatment of isolated SEGA. 
      Further study is warranted.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Appalla, Deepika
AU  - Appalla D
AD  - Division of Pediatric Hematology and Oncology, Department of Paediatrics, The 
      Children's Hospital at Saint Peter's University Hospital, New Brunswick, New 
      Jersey.
FAU - Depalma, Andres
AU  - Depalma A
AD  - University Radiology, Saint Peter's University Hospital, New Brunswick, New 
      Jersey.
FAU - Calderwood, Stanley
AU  - Calderwood S
AD  - Division of Pediatric Hematology and Oncology, Department of Paediatrics, The 
      Children's Hospital at Saint Peter's University Hospital, New Brunswick, New 
      Jersey.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160301
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Astrocytoma/diagnostic imaging/*drug therapy/enzymology
MH  - Brain Neoplasms/diagnostic imaging/*drug therapy/enzymology
MH  - Child
MH  - Everolimus/*administration & dosage
MH  - Humans
MH  - Male
MH  - Remission Induction
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - *Tuberous Sclerosis
OTO - NOTNLM
OT  - biological response modifier
OT  - gliomas
OT  - low grade
OT  - rare tumors
EDAT- 2016/03/02 06:00
MHDA- 2017/03/18 06:00
CRDT- 2016/03/02 06:00
PHST- 2015/08/31 00:00 [received]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2017/03/18 06:00 [medline]
AID - 10.1002/pbc.25964 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2016 Jul;63(7):1276-8. doi: 10.1002/pbc.25964. Epub 2016 
      Mar 1.